Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
Trial · NCT01001572
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Single-Blind Valsartan 160 mg | STARTED | Single-Blind Run -In Valsartan 160 mg | 932 | |
| Single-Blind Valsartan 160 mg | STARTED | Valsartan/Amlodipine 160/5 mg | 0 | |
| Single-Blind Valsartan 160 mg | STARTED | Valsartan 160 mg | 0 | |
| Single-Blind Valsartan 160 mg | COMPLETED | Single-Blind Run -In Valsartan 160 mg | 654 | |
| Single-Blind Valsartan 160 mg | COMPLETED | Valsartan/Amlodipine 160/5 mg | 0 | |
| Single-Blind Valsartan 160 mg | COMPLETED | Valsartan 160 mg | 0 | |
| Single-Blind Valsartan 160 mg | NOT COMPLETED | Single-Blind Run -In Valsartan 160 mg | 278 | |
| Single-Blind Valsartan 160 mg | NOT COMPLETED | Valsartan/Amlodipine 160/5 mg | 0 | |
| Single-Blind Valsartan 160 mg | NOT COMPLETED | Valsartan 160 mg | 0 | |
| Double-Blind Treatment Phase | STARTED | Single-Blind Run -In Valsartan 160 mg | 0 | |
| Double-Blind Treatment Phase | STARTED | Valsartan/Amlodipine 160/5 mg | 329 | |
| Double-Blind Treatment Phase | STARTED | Valsartan 160 mg | 325 | |
| Double-Blind Treatment Phase | Full Analysis Set (FAS) | Single-Blind Run -In Valsartan 160 mg | 0 | |
| Double-Blind Treatment Phase | Full Analysis Set (FAS) | Valsartan/Amlodipine 160/5 mg | 328 | |
| Double-Blind Treatment Phase | Full Analysis Set (FAS) | Valsartan 160 mg | 323 | |
| Double-Blind Treatment Phase | COMPLETED | Single-Blind Run -In Valsartan 160 mg | 0 | |
| Double-Blind Treatment Phase | COMPLETED | Valsartan/Amlodipine 160/5 mg | 319 | |
| Double-Blind Treatment Phase | COMPLETED | Valsartan 160 mg | 306 | |
| Double-Blind Treatment Phase | NOT COMPLETED | Single-Blind Run -In Valsartan 160 mg | 0 | |
| Double-Blind Treatment Phase | NOT COMPLETED | Valsartan/Amlodipine 160/5 mg | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01001572/flow